Effect of Neoadjuvant Chemotherapy on Cardiac Function of Perioperative Patients With Breast Cancer and New Strategies for Anesthesia

Launched by FUJIAN MEDICAL UNIVERSITY UNION HOSPITAL · Jul 4, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring how neoadjuvant chemotherapy (treatment given before surgery) affects heart function in patients with breast cancer, especially during the time around their surgery (the perioperative period). The researchers want to understand better how chemotherapy impacts the heart and to improve anesthesia methods to keep patients' hearts safe during surgery. They will be looking at patients’ heart performance before and after chemotherapy and how different anesthesia strategies can help protect the heart during the surgical process.

To participate in this study, individuals need to be at least 18 years old and have a specific heart function level before and after receiving chemotherapy. They should also be able to understand and follow the study procedures. However, some people may not be eligible, including those with certain heart diseases, severe organ problems, or allergies to the study medications. Participants can expect to receive careful monitoring of their heart health and to contribute valuable information that could help improve care for future patients undergoing similar treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Aged 18 and above;
• • 2. Left ventricular ejection fraction shall not be less than 45% before neoadjuvant chemotherapy and not less than 40% after neoadjuvant chemotherapy;
• • 3. The electrocardiogram shows sinus rhythm;
• • 4. Acetylsalicylic acidlevel I to III;
• • 5. Can understand and cooperate with the research process.
• Exclusion Criteria:
• • 1. Patients with congenital organic heart disease, arrhythmia requiring intervention, heart valve disease, cardiomyopathy, high atrioventricular and bundle branch block, history of myocardial infarction, severe hypertension, long-term diabetes and other diseases affecting heart function;
• • 2. Patients with severe dysfunction of important organs such as liver and kidney, who are intolerant to neoadjuvant chemotherapy or surgical anesthesia;
• • 3. Patients who are allergic to the drugs used in this study;
• • 4. Patients with mental illness, consciousness disorders, and communication barriers;
• • 5. Patients with severe coagulation dysfunction;
• • 6. Patients who have used monoamine oxidase inhibitors within two weeks prior to anesthesia surgery;
• • 7. Patients who refused to participate in this study.